



## OPINION ARTICLE

# Open laboratory notebooks: good for science, good for society, good for scientists [version 1; referees: awaiting peer review]

Matthieu Schapira<sup>1,2</sup>, The Open Lab Notebook Consortium, Rachel J. Harding <sup>1</sup>

<sup>1</sup>Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada

<sup>2</sup>Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, M5G 1L7, Canada

---

**v1** **First published:** 22 Jan 2019, 8:87 (<https://doi.org/10.12688/f1000research.17710.1>)  
**Latest published:** 22 Jan 2019, 8:87 (<https://doi.org/10.12688/f1000research.17710.1>)

---

## Abstract

The fundamental goal of the growing open science movement is to increase the efficiency of the global scientific community and accelerate progress and discoveries for the common good. Central to this principle is the rapid disclosure of research outputs in open-access peer-reviewed journals and on pre-print servers. The next bold step in this direction is open laboratory notebooks, where research scientists share their research — including detailed protocols, negative and positive results — online and in near-real-time to synergize with their peers. Here, we highlight the benefits of open lab notebooks to science, society and scientists, and discuss the challenges that this nascent movement is facing. We also present the implementation and progress of our own initiative at [openlabnotebooks.org](http://openlabnotebooks.org), with more than 20 active contributors after one year of operation.

## Keywords

open lab notebooks, open science, peer-review, preprints, publishing, science communication

## Open Peer Review

**Referee Status:** *AWAITING PEER*

*REVIEW*

---

## Discuss this article

Comments (0)



This article is included in the [Science Policy Research gateway](#).

**Corresponding authors:** Matthieu Schapira ([matthieu.schapira@utoronto.ca](mailto:matthieu.schapira@utoronto.ca)), Rachel J. Harding ([rachel.harding@utoronto.ca](mailto:rachel.harding@utoronto.ca))

**Author roles:** Schapira M: Supervision, Writing – Original Draft Preparation; Harding RJ: Conceptualization, Investigation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** The Structural Genomics Consortium (SGC) is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and The Wellcome Trust [106169/ZZ14/Z]. RJH is a recipient of the HDSA Berman/Topper HD Career Development Fellowship. PR is funded by the Wellcome Trust Leicester ISSF award reference 204801/Z/16/Z and the Leicester Institute of Chemical and Structural Biology (LISCB).

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2019 Schapira M *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Schapira M, The Open Lab Notebook Consortium and Harding RJ. **Open laboratory notebooks: good for science, good for society, good for scientists [version 1; referees: awaiting peer review]** *F1000Research* 2019, 8:87 (<https://doi.org/10.12688/f1000research.17710.1>)

**First published:** 22 Jan 2019, 8:87 (<https://doi.org/10.12688/f1000research.17710.1>)

## Introduction

The function of the scientific peer-reviewed system is to provide greater confidence that published research is scientifically sound. This system is widely accepted as the best available, although imperfect (as peer reviewers may miss technical flaws or be biased)<sup>1</sup>, to guide the global scientific community towards progress. Peer-reviewed publishing is also used by research scientists, funders and institutions as a mechanism to claim ownership of their discoveries. As a result, the community widely believes that findings should be kept secret until they are published in a peer-reviewed journal. This tradition of secrecy, which protects the scientist as opposed to the science, has been transmitted from mentor to trainee for centuries (Galileo kept his discoveries to himself until they were published). In the life sciences, this belief can reach near-mystical levels<sup>2</sup>. The peer-review and publication process grew in an era where communication was largely in paper format. Today, in the age of instant communication, one would imagine there should be more efficient ways to operate.

## Open lab notebooks: good for science and society

We believe that open laboratory notebooks, where research scientists record their work online and in near-real time, are an efficient way to disseminate data before it is published in peer-reviewed journals, and has several advantages over the traditional “release after publication” system<sup>3</sup>. First, making the data accessible within weeks rather than keeping it hidden for years means that others will be able to build upon the research, and avoid spending time and resources on redundant experiments<sup>4</sup>. Second, open lab notebooks should include detailed protocols that can be reproduced, which is often not the case in peer-reviewed publications<sup>5,6</sup>. Third, negative data, which are almost never disclosed in the current publishing system but are provided in open lab notebooks, can sometime provide important insight<sup>7,8</sup>. Fourth, open lab notebooks offer a space for anyone to comment on experimental records. This allows experts to provide insight, but also to flag technically unsound experiments, thereby reducing the potential for flawed science to appear in peer-reviewed journals and in pre-print media. Open lab notebooks can therefore help save time, resources, and knowledge. If adopted by many, they should lead to a more synergistic way to do science and to more efficient use of public funds.

## Good for scientists

Many believe that openly sharing work online will limit career opportunities. We argue that open lab notebooks have compensating advantages that are good for scientists. To succeed in academia, one must get funding, assert primacy over discoveries, be known in a field of research and be able to present work and ideas clearly and convincingly. Open lab notebooks can help in all aspects.

First, funding agencies are seeing the open science movement as a long lasting and far-reaching shift for the best, and are increasingly supportive of efforts to embrace open science principles. For instance, the symposium set to launch [openlabnotebooks.org](https://openlabnotebooks.org) was entirely sponsored by the Wellcome Trust and the Canadian Institute of Health Research, and senior representatives from the Gates Foundation and the

Chan-Zuckerberg Initiative were also in attendance (<https://www.thesgc.org/open-lab-notebooks-2018>). The NIH’s National Institute on Aging dedicated an entire session to open science at their 2018 Alzheimer’s research summit (<https://www.nia.nih.gov/research/nih-ad-summit-2018-program-agenda>), as did the 2018 Enroll-HD congress of the CHDI Huntington’s Disease Foundation (<https://www.enroll-hd.org/enroll-hd-congress-2018/>). The Wellcome Trust has recently launched the [Wellcome Open Research](#) publishing platform and [Open Research Fund](#). Grant applications that highlight the use of open lab notebooks are being viewed positively. For example, Huntington’s disease (HD) research funders such as the CHDI Foundation, the Huntington Society of Canada and the Huntington Society of America, have all generously funded studies of HD biochemistry at the SGC Toronto.

Second, results in open lab notebook are date-stamped, thus claiming temporal priority of the data. Indeed, public repositories such as Zenodo<sup>9</sup> add a date-stamp to depositions, and assign a citable DOI to open lab notebook records (detailed below).

Third, early career scientists can use their open notebooks to connect with their peers and with experts in the field, start new collaborations and build their own network. Fourth, the use of open lab notebooks provides opportunity to present work clearly and concisely to both experts and non-experts. This is an important skill to master in order to write convincing grant applications. Fifth, junior scientists will also find their open lab notebook a good medium to showcase their technical skills and scientific insight, and may find it useful to add a link in their resume when applying for their next position. Finally, many will find a personal satisfaction in embracing open science and FAIR data principles<sup>10</sup>.

## Implementation of an open lab notebook platform

Following our prediction that open lab notebooks should be good for science and good for scientists, and after a 2-year pilot study where Rachel Harding, a post-doctoral fellow at the Structural Genomics Consortium (SGC) shared her work on Huntington’s disease at [labscribbles.com](https://labscribbles.com) (<https://www.vox.com/2016/3/3/11148452/science-blog>), we launched [openlabnotebooks.org](https://openlabnotebooks.org) in January 2018, where 12 scientists from the SGC started reporting their work live, online<sup>11,12</sup>. Each post is composed of two documents. (1) A detailed and rigorous experimental record, including all data and protocols, which experts can evaluate, comment on or build upon ([Figure 1](#)); (2) a blog, aimed at the non-specialist that explains in simple terms the motivation and rationale for the experiment, summarizes results – positive and negative – and outlines next steps ([Figure 2](#)). The blogs, posted at [openlabnotebooks.org](https://openlabnotebooks.org), are managed by a webserver downloaded from [wordpress.org](https://wordpress.org) and link to the experimental records, which are deposited at Zenodo ([zenodo.org](https://zenodo.org)), but can also be made available from other public repositories, such as GitHub ([github.com](https://github.com)) or Figshare ([figshare.com](https://figshare.com)). The Zenodo repository enables sharing research outputs from across all fields of research, creation and curation of complete digital repositories, flexible licensing with controlled degree of openness and safe storage of the data for the future in the same cloud infrastructure

# Viability screen of ACVR1/ALK2 inhibitory compounds on Diffuse Intrinsic Pontine Glioma cells

Elizabeth Brown, Gillian Farnie, Alex Bullock

6 compounds developed by M4K Pharma to inhibit the ACVR1/ALK2 tyrosine kinase were tested for their ability to reduce viability of both mutant and wild-type ACVR1 DIPG cell lines (HSJD-DIPG-007 and HSJD-DIPG-011 respectively). Compounds were tested on cells grown as 2D sheets and 3D neurospheres, as well as with and without radiation treatment. M4K2009 was highly effective in ACVR1 mutant DIPG cells, but this was not the case in ACVR1 wild-type cells.

**Funding Acknowledgment:** The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.

Preview

Page: 2 of 7 Automatic Zoom

**Day 7**  
Scan cells with image cytometer to record final confluence/sphere diameter and propidium iodide intensity. Harvest cells with CellTiter-Glo® 3D (for all cells and all conditions) as a measure of culture viability according to [manufacturer's instructions](#).

**Data analysis**  
All values were normalised to the average of the vehicle controls on the plate (or the plate divided into sections using the vehicle controls, if visible variation across the plate).

**Results**  
In the mutant ACVR1 cell line HSJD-DIPG-007 the most effective probe is M4K2009 (with the caveat that this dataset only includes one biological repeat), with all M4K2000 series compounds being more effective than M4K3000 series compounds (Figure 1). Comparison of additional end point read outs such as confluency or cell death supports this ranking (Figure 2). Consideration of the effectiveness of each compound in different growth conditions i.e. 2D vs 3D and with or without radiation treatment suggests that M4K2043 and M4K2096 may be less effective in addition to radiation, however M4K2009 remains highly efficient at killing HSJD-DIPG-007 cells (Figure 3). Results in the ACVR1 WT HSJD-DIPG-011 cell line were more variable but indicate that M4K2009 is less effective, with M4K2096 in this case being the most effective probe (Figure 4). These contrasting screen results could indicate that the effectiveness of M4K ACVR1 inhibitory compounds could be dependent on the mutations present. For the HSJD-DIPG-011 cell line, in two out of three biological repeat viability and confluence results are concurrent (Figure 5). Comparison of growth conditions in the HSJD-DIPG-011 cell line is difficult because of the variation

Files (553.7 kB)

Name	Size	Preview	Download
DIPG_cell_M4K_compound_screen_181206.pdf	553.7 kB		

md5:d789819fa3d9dcf0c2938bf154271273

74 views 31 downloads

See more details...

7 Tweeted by 10

See more details

Indexed in

OpenAIRE

**Publication date:**  
December 6, 2018

**DOI:**  
DOI: [10.5281/zenodo.2000673](https://doi.org/10.5281/zenodo.2000673)

**Keyword(s):**  
dipg diffuse intrinsic pontine glioma m4k pharma compound screen viability assay acvr1 alk2

**Communities:**  
[Open Notebooks](#)  
[SGC Open Notebooks](#)

**License (for files):**  
[Creative Commons Attribution 4.0 International](#)

**Versions**

Version 1 10.5281/zenodo.2000673 Dec 6, 2018

**Cite all versions?** You can cite all versions by using the DOI [10.5281/zenodo.2000672](https://doi.org/10.5281/zenodo.2000672). This DOI represents all versions, and will always resolve to the latest one. [Read more](#).

**Share**

**Cite as**  
Brown, Elizabeth, Farnie, Gillian & Bullock, Alex. (2018). Viability screen of ACVR1/ALK2 inhibitory compounds on Diffuse Intrinsic Pontine Glioma cells. <http://doi.org/10.5281/zenodo.2000673>

Start typing a citation style...

**Figure 1. Detailed experimental records including protocols, positive and negative data are posted on Zenodo.** A citable DOI is automatically generated (right-middle panel), and the number of visits and downloads provided (top right).

as CERN's own LHC research data. While the experimental details posted at Zenodo are important scientifically, the blog written in layman's term can be used to engage with scientists that may have a complementary set of expertise for future collaborations as well as other stakeholders in the research process, including patient groups, a dimension that most in academia are missing.

The ultimate goal of this open lab notebook initiative is not only to increase the impact of our work but also, along with precursors in the field such as Open Source Malaria

(<http://opensource malaria.org/>) and other isolated open lab notebook efforts, to inspire others to follow, and contribute to the creation of a new open science movement in the life sciences. While it is too early to judge the success of this initiative, the number of contributing scientists and institutions is steadily increasing (Figure 3). While only one scientist was contributing in November 2017, 23 scientists from six institutions (University of Toronto, University of Oxford, University of North Carolina, University of Leicester, the Karolinska Institute in Sweden and University of Montpellier in France) are recording their work at openlabnotebooks.org as of December 2018.

## Screening ACVR1 inhibitors on mutant and non-mutant ACVR1 DIPG cells – effectiveness may vary

7th December 2018 Elizabeth Brown [Leave a comment](#)

Hi there! The last month of my life was taken over by making sure my PhD first year report was beautifully polished, but I have returned with results of a small compound screen:

These are all compounds that [Jong Fu](#) has already tested with his assays so we know they effectively inhibit ACVR1, but I thought it would be a good idea to try them out on my DIPG cells and see how well they can kill them. I included a few different variables in this screen to test what could make a difference to the outcome:


- I tested cells grown in 2D and 3D because this has been noted to change the outcome of compound screens in other systems
- I tested the compounds alone, or in addition to radiation in order to test whether the compounds were effective in addition to current DIPG treatments.

I tested how effective each compound is by growing cells for 7 days in the presence of the compound. At the end I measured how alive or healthy the cells were (i.e. their viability) by using a pre-developed kit that measures the amount of ATP inside the cell by using an enzyme that can produce light when ATP is present. ATP is measured because this is sometimes called the 'energy currency of the cell' so living cells have to have ATP inside them, whereas dead cells won't and won't be counted.

From that heatmap you can see that M4K2009 is the best at killing ACVR1 mutant cells (the top heatmap), but it isn't as effective in cells where the ACVR1 gene is not mutated ("wild-type" cells). In those cells instead M4K2096 is the most effective compound (but still not to the same extent as M4K2009).

But this is only the data for cells grown in 2 dimensions without a radiation treatment. If you want to see the full dataset, you can read my [Zenodo post!](#)

ACVR1/ALK2, Brain Tumours, Diffuse intrinsic pontine glioma, Liz Brown, Understudied Kinases




As importantly, impact is also increasing, judging by the average number of views per experimental record calculated from statistical data available at Zenodo.org (Figure 3). Some reports raised a considerable interest. For instance, the crystal structure of USP5 in complex with small molecule fragments has 821 unique views and 324 unique downloads as of December 2018<sup>13</sup>. If the initiative is successful, we anticipate that within three to five years, usage metrics are comparable at openlabnotebooks.org and bioRxiv, the preprint server for biology.

Data posted at openlabnotebooks.org are raising interest in academic groups, but also in the industry. For instance, a notebook contributor was directly contacted by a big pharmaceutical company to further discuss the results that he had shared online, and a big biotech company asked permission to another contributor to include their data in a presentation at a public scientific meeting. Some of the research reported at

openlabnotebooks.org is of direct relevance to patient groups. For instance, four scientists record their results on testing chemical inhibitors of the kinase ALK2, a potential therapeutic target for the treatment of the pediatric brain tumor diffuse intrinsic pontine glioma (DIPG), and the heterotopic ossification disorder fibrodysplasia ossificans progressiva (FOP)<sup>14,15</sup>. The compounds, developed by the open science biotech company M4KPharma, are still in pre-clinical phase of development but should ultimately lead to clinical trials for these incurable diseases<sup>16</sup>. Scientists working on projects with a clear path to the clinic are eager to share their enthusiasm and commitment with patient groups (sometimes using social media to announce their latest open notebook post) who, in turn, follow their work.

### The challenges of open lab notebooks

Three antagonizing points that inhibit scientists from starting their own open lab notebook are the fear of being scooped, the inability to report collaborative work when collaborators want



**Figure 3. Information on openlabnotebooks.org.** The Number of (a) scientists and (b) institutions actively contributing to openlabnotebooks.org. (c) The average number of unique visits for each experimental record.

to keep data secret, and the concern that an open notebook will take time away from an already overburdened schedule<sup>17</sup>. The language barrier for non-native English speakers, and the availability of open lab notebook solutions can also be challenging. It is indeed likely that maintaining an open lab notebook increases the chances of being scooped, but it is too early at this point to know whether this effect is minor or significant. Paradoxically, and given the territorial nature of the current frameworks for funding and managing scientific research, entries in one's open lab notebook may mark one's area very effectively, especially in a conceivable future when funding trusts and councils start looking into them. We would argue that most, if not all, scientists get scooped during their career, and that open lab notebooks serve as a safety net for early career scientists who have a citable record of their work if they ever get scooped. Obtaining permission from collaborators to report collaborative work in open lab notebooks can be challenging. We believe that the best way to avoid such a situation is to clearly state at the outset of a collaboration the intention to adopt open science principles<sup>18</sup>. Scientists are more likely to agree if presented with the idea well in advance. The time invested in practicing clear, concise and engaging scientific writing is not lost on one's career. After some practice, maintaining an open lab notebook should not take more time than using a regular lab notebook.

### Future directions and conclusion

Open lab notebooks represent a major departure from current practices in science (especially biomedical sciences) and hold a mix of promises and risks. As the community producing these lab notebooks is increasing, there is an opportunity to move beyond ideology and anecdotal data to evidence-based policy design. In the spirit of openness, we call on colleagues from both the life science and the social sciences communities to conduct systematic evaluation of the benefits and downsides of open lab notebooks. It will be important to compare several parameters on a yearly basis. These may include the frequency of research being scooped among scientists disclosing their work in open lab notebooks versus a less open reference group; the frequency of new collaborations; the frequency of comments and ideas received by the authors of open notebooks; and instances where open lab notebooks were essential for compliance with funder or institutional requirements. More difficult to assess will be issues such as recognition, career progression,

speeding up research, and impact on reproducibility, but they could all be addressed with appropriate questionnaires and data analytics.

Our goal is to see the number of open lab notebooks increase exponentially over the coming years. Future implementation of novel features, such as the ability to search for experiments containing compounds with specific chemical templates, is expected to extend the reach of the platform to medicinal and computational chemists. Indexing of open lab notebooks by popular search engines such as Google Scholar (which already indexes pre-prints and other non-peer-reviewed documents) would increase the visibility and impact of open notebooks. Importantly, open lab notebook data deposited at Zenodo.org is already searchable with [Google's Dataset search engine](#). To further encourage scientists to break free from the tradition of secrecy that has been passed on for generations, a cultural change needs to be supported at institutional and governmental levels. Funding bodies are starting to define and enforce open science publication practices<sup>19</sup>. Similarly, universities could take a more proactive role, for instance by including adherence to open-access principles as an evaluation criteria for career advancement<sup>20</sup>. Indeed, while strong incentives described above already exist for junior scientists to start their own open lab notebook, the benefit to their PIs who already have established a professional network and don't need to showcase their skills is not always as clear. As long as scientists are not convinced that open science is good for them, Science 2.0 will have to wait.

### Data availability

No data are associated with this article

### Grant information

The Structural Genomics Consortium (SGC) is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP,

Takeda, and The Wellcome Trust [106169/ZZ14/Z]. RJH is a recipient of the HDSA Berman/Topper HD Career Development Fellowship. PR is funded by the Wellcome Trust Leicester ISSF award reference 204801/Z/16/Z and the Leicester Institute of Chemical and Structural Biology (LISCB).

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

## Acknowledgments

We thank the following principal investigators whose group members are contributing to openlabnotebooks.org: Cheryl Arrowsmith, Dalia Barsyte, Paul Brennan, Alex Bullock,

David Drewry, Susanne Gräslund, Brian Marsden, Dave Morris, Panagiotis Prinos, Frank Von Delft, Tim Willson, and Wyatt Yue.

The Open Lab Notebook Consortium is made up of Roslin Adamson, Jose Brandao-Neto, Elizabeth J. Brown, Antoine Claessens, David Damerell, David Dilworth, Thomas Durcan, Benjamin J. Edulful, Aled M. Edwards, Opher Gileadi, Jolene Caifeng Ho, Leonidas Koukoufliis, Tobias Krojer, Genna M. Luciani, Sabrina Mackinnon, Mandeep Mann, Carolyn Marks, Sean O'Byrne, Alfredo Picado, Pietro Roversi, Louisa Temme, Eleanor Williams, Jong Fu Wong, Wen Yih Aw.

## References

- Smith R: **Peer review: a flawed process at the heart of science and journals.** *J R Soc Med.* 2006; **99**(4): 178–82.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Resnik DB: **Openness versus Secrecy in Scientific Research Abstract.** *Episteme (Edinb).* 2006; **2**(3): 135–147.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Woelfle M, Oliaro P, Todd MH: **Open science is a research accelerator.** *Nat Chem.* 2011; **3**(10): 745–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Powell K: **Does it take too long to publish research?** *Nature.* 2016; **530**(7589): 148–51.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Wallach JD, Boyack KW, Ioannidis JPA: **Reproducible research practices, transparency, and open access data in the biomedical literature, 2015–2017.** *PLoS Biol.* 2018; **16**(11): e2006930.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Reality check on reproducibility.** *Nature.* 2016; **533**(7604): 437.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Mlinari A, Horvat M, Šupak Smolčić V: **Dealing with the positive publication bias: Why you should really publish your negative results.** *Biochem Med (Zagreb).* 2017; **27**(3): 030201.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Carroll HA, Toumpakari Z, Johnson L, et al.: **The perceived feasibility of methods to reduce publication bias.** *PLoS One.* 2017; **12**(10): e0186472.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Nielsen LH: **Sharing your data and software on Zenodo.** 2017.
- Wilkinson MD, Dumontier M, Aalbersberg IJ, et al.: **The FAIR Guiding Principles for scientific data management and stewardship.** *Sci Data.* 2016; **3**: 160018.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Open notebooks galore: The Structural Genomics Consortium.** *eLife.* [Accessed: 24-Dec-2018] 2018.  
[Reference Source](#)
- Schapiro M: **Open Lab Notebooks to increase impact and accelerate discovery.** *Research Data at Springer Nature.* [Accessed: 24-Dec-2018] 2018.  
[Reference Source](#)
- Mann M, Harding R, Ravichandran M, et al.: **Co-crystal structures of USP5 Zf-UBD and weak binding compounds.** *Zenodo.* 2018.  
[Publisher Full Text](#)
- van Dinther M, Visser N, de Gorter DJ, et al.: **ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.** *J Bone Miner Res.* 2010; **25**(6): 1208–1215.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Taylor KR, Vinci M, Bullock AN, et al.: **ACVR1 Mutations in DIPG: lessons learned from FOP.** *Cancer Res.* 2014; **74**(17): 4565–4570.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Morgan MR, Roberts OG, Edwards AM: **Ideation and implementation of an open science drug discovery business model – M4K Pharma.** *Wellcome Open Res.* 2018; **3**: 154.  
[Publisher Full Text](#)
- Robertson MN, Ylloja PM, Williamson AE, et al.: **Open source drug discovery - a limited tutorial.** *Parasitology.* 2014; **141**(1): 148–157.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Masum H, Rao A, Good BM, et al.: **Ten simple rules for cultivating open science and collaborative R&D.** *PLoS Comput Biol.* 2013; **9**(9): e1003244.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Eise H: **Radical open-access plan could spell end to journal subscriptions.** *Nature.* 2018; **561**(7721): 17–18.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Alperin JP, Fischman GE, McKiernan EC, et al.: **How significant are the public dimensions of faculty work in review, promotion, and tenure documents?** 2018.  
[Publisher Full Text](#)

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

**F1000Research**